What is the ‘golden dose’ and what are the risks? Medical News Today asks four experts to weigh in on the trend of trying to ...
Presenters at the AAO discussed phase 2 clinical trial results evaluating the safety and efficacy of foselutoclax (UBX1325) compared with aflibercept in diabetic macular edema.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback